Regeneron, Sanofi Get Speedy FDA Review of Dupixent in COPD
By Colin Kellaher
Regeneron Pharmaceuticals and Sanofi have won U.S. Food and Drug Administration priority review for their application seeking expanded approval of Dupixent in chronic obstructive pulmonary disease, potentially adding a sixth U.S. indication for their blockbuster anti-inflammatory drug.
Regeneron and Sanofi on Friday said the application covers Dupixent as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease, or COPD.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. The agency has set a target action date of June 27 for the application.
Regeneron and Sanofi said an FDA green light would make Dupixent the only biologic therapy for COPD and the first new treatment approach for the disease in more than a decade.
Regulatory submissions also are under review in China and Europe, the companies said.
Tarrytown, N.Y., biotechnology company Regeneron created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement, while Sanofi markets the product internationally. The drug generated roughly $11.6 billion in sales last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 23, 2024 06:15 ET (11:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How the Tokyo Stock Exchange Is Pushing for Better Capital Allocation
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting